Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

被引:0
作者
Gary Burgess
Hans Hoogkamer
Lorraine Collings
Jasper Dingemanse
机构
[1] PGRD,
[2] Pfizer Ltd,undefined
[3] Actelion Pharmaceuticals Ltd,undefined
来源
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词
Bosentan; Combination therapy; Pharmacokinetics; Sildenafil;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:43 / 50
页数:7
相关论文
共 79 条
[1]  
Farber HW(2004)Pulmonary arterial hypertension N Engl J Med 351 1655-1665
[2]  
Loscalzo J(2004)Treatment of pulmonary arterial hypertension N Engl J Med 351 1425-1436
[3]  
Humbert M(1996)A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 296-302
[4]  
Sitbon O(2002)Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 800-804
[5]  
Simonneau G(1999)Cyclic GMP phosphodiesterase-5: Target of sildenafil J Biol Chem 274 13729-13732
[6]  
Barst RJ(2005)Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells Basic Res Cardiol 100 131-138
[7]  
Rubin LJ(2001)Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study Lancet 358 1119-1123
[8]  
Long WA(2002)Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 896-903
[9]  
Simonneau G(2005)Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2148-2157
[10]  
Barst RJ(2005)Endothelin antagonism in pulmonary arterial hypertension Semin Respir Crit Care Med 26 402-408